Skip to main content
Retour
Watch Compare

Oncotelic Therapeutics, Inc.

Qualité des données : 100%
OTLC
OTC Manufacturing Chemicals
0,04 €
0,00 € (0,00%)
Cap. Boursière: 17,70 M
Prix
0,04 €
Cap. Boursière
17,70 M
Fourchette du Jour
0,04 € — 0,04 €
Fourchette 52 Semaines
0,02 € — 0,11 €
Volume
44 500
Ouverture 0,04 €
Moyenne 50J / 200J
0,05 €
20,63% below
Moyenne 50J / 200J
0,07 €
40,03% below

Quick Summary

Points Clés

Revenue declined -55,22% annually over 5 years
Negative free cash flow of -704 008,0
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 55,22%

Croissance

Revenue Growth (5Y)
-55,22%
En dessous de la moyenne du secteur (1,82%)
Revenue (1Y)0,00%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-19,24%
Au-dessus de la moyenne du secteur (-53,47%)
ROIC-5,21%
Net MarginN/A
Op. MarginN/A

Sécurité

Debt / Equity
N/A
Current Ratio0,08
Interest CoverageN/A

Valorisation

PE (TTM)
-10,61
En dessous de la moyenne du secteur (-1,47)
P/B Ratio1,96
EV/EBITDAN/A
Dividend YieldN/A

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1364 pairs)
Métrique Action Médiane du Secteur
P/E -10,6 -1,5
P/B 2,0 1,6
ROE % -19,2 -53,5
Net Margin % — -41,5
Rev Growth 5Y % -55,2 1,8
D/E — 0,3

All Fundamental Metrics
Growth
Revenue Growth (1Y) 0,00% Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -55,22% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 0,0 Net Income (TTM) -1,67 M
ROE -19,24% ROA -6,09%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -704 008,0
ROIC -5,21% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 0,08
Interest Coverage N/A Asset Turnover 0,00
Working Capital -18,47 M Tangible Book Value 6,26 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -10,61 Forward P/E N/A
P/B Ratio 1,96 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -3,98%
Market Cap 17,70 M Enterprise Value 17,29 M
Per Share
EPS (Diluted TTM) N/A Revenue / Share 0,00
FCF / Share 0,00 OCF / Share 0,00
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 42,18%
SBC-Adj. FCF -887 750 Growth Momentum 55,22

Income Statement

Annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2019
Revenue 70 000,0 70 000,0 — 1,74 M —
Net Income -4,52 M -7,90 M 5,09 M -9,39 M -6,64 M
EPS (Diluted) — -0,02 0,01 — —
Gross Profit — — — — —
Operating Income -3,58 M -6,65 M -9,72 M -9,13 M -4,31 M
EBITDA — — — — —
R&D Expenses — 61 143,0 756 910,0 3,66 M 1,37 M
SG&A Expenses — — — — —
D&A — — — — —
Interest Expense — 1,04 M 2,97 M 2,00 M 749 602,0
Income Tax — — — — —

Balance Sheet

Annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 26,68 M 30,01 M 36,12 M 23,61 M 23,66 M
Total Liabilities 19,20 M 18,40 M — — —
Shareholders' Equity 8,25 M 12,13 M 19,41 M 7,96 M 11,77 M
Total Debt 2,42 M 1,77 M 390 050,0 359 262,0 95 000,0
Cash & Equivalents — 170 405,0 241 452,0 568 769,0 474 019,0
Current Assets 134 211,0 271 737,0 303 164,0 627 295,0 615 636,0
Current Liabilities 19,20 M 16,50 M 16,92 M 15,45 M 11,18 M